Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin

The most effective regimen for patients with acute myeloid leukemia (AML) who do not achieve complete remission (CR) after one course of cytarabine and an anthracycline has not been extensively studied. We evaluated restrospectively the efficacy, toxicity, and prognostic factors for the achievement of CR following mitoxantrone and etoposide in 74 patients with newly diagnosed AML who did not respond to one course of therapy with cytarabine and idarubicin. CR was achieved in 39% of patients; 14% died of infectious complications; no grade 3 or 4 hepatic toxicities were observed. Median duration of overall survival was 9.0 months (95% CI 5.8–14.9 months). The median duration of relapse-free survival was 11.0 months (95% CI: 9.0–19.3 months). A lower CR rate was associated with unfavorable risk status at diagnosis and higher percent blasts. Our data suggest that the combination of etoposide and mitoxantrone is an effective second-course therapy in patients with newly diagnosed AML.

[1]  H. Kantarjian,et al.  Progress in the treatment of acute myeloid leukemia , 2007, Cancer.

[2]  E. Estey,et al.  Adult acute myeloid leukemia. , 2006, Mayo Clinic proceedings.

[3]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[4]  J. Lipton,et al.  Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? , 2005, Bone Marrow Transplantation.

[5]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Nademanee,et al.  A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  D. Blaise,et al.  Outcome of Adult Patients with Acute Myeloid Leukemia who Failed to Achieve Complete Remission after one Course of Induction Chemotherapy: A Report from the BGMT Study Group: For the BGMT , 2001, Leukemia & lymphoma.

[8]  R. Peto,et al.  A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia , 1998, British journal of haematology.

[9]  E. Thiel,et al.  Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. , 1994, Leukemia & lymphoma.

[10]  A. Rimm,et al.  Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. , 1992, Blood.

[11]  E. Estey,et al.  Mitoxantrone and high‐dose etoposide for patients with relapsed or refractory acute leukemia , 1991, Cancer.

[12]  C. Schiffer,et al.  Mitoxantrone and Constant Infusion Etoposide for Relapsed and Refractory Acute Myelocytic Leukemia , 1990, American journal of clinical oncology.

[13]  M. Lazzarino,et al.  Mitoxantrone and etoposide: An effective regimen for refractory or relapsed acute myelogenous leukemia , 1989, European journal of haematology.

[14]  T. Lipp,et al.  Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Oken,et al.  A phase II trial of VP 16–213 in adults with refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group study , 1984, American journal of clinical oncology.

[16]  R. Silver,et al.  Mitoxantrone in patients with acute leukemia in relapse. , 1983, Cancer research.

[17]  E. Estey,et al.  Phase II trial of mitoxantrone in refractory acute leukemia. , 1983, Cancer treatment reports.

[18]  I. Smith,et al.  VP 16-213 in acute myelogenous leukaemia , 1976, Postgraduate medical journal.

[19]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.

[20]  E. Estey,et al.  Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. , 1996, Leukemia.

[21]  P. Sonneveld,et al.  Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). , 1994, Leukemia.

[22]  G. Ehninger,et al.  Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. , 1990, Haematology and blood transfusion.